Anticancer drugs: where are we now?
- 15 May 2024
- journal article
- editorial
- Published by Taylor & Francis in Expert Opinion on Therapeutic Patents
- Vol. 34 (7) , 525-527
Abstract
No abstract availableKeywords
This publication has 28 references indexed in Scilit:
- The high, and redundant, cost of failure in cancer drug developmentNature Reviews Drug Discovery, 2023
- Cancers make their own luck: theories of cancer originsNature Reviews Cancer, 2023
- Deciphering the key heterocyclic scaffolds in targeting microtubules, kinases and carbonic anhydrases for cancer drug developmentPharmacology & Therapeutics, 2021
- Natural products in drug discovery: advances and opportunitiesNature Reviews Drug Discovery, 2021
- The Discovery of Obeticholic Acid (Ocaliva™): First‐in‐ClassFXRAgonist2018
- The Emerging Hallmarks of Cancer MetabolismCell Metabolism, 2016
- A Small‐Molecule Drug Conjugate for the Treatment of Carbonic Anhydrase IX Expressing TumorsAngewandte Chemie International Edition, 2014
- The NAD metabolome — a key determinant of cancer cell biologyNature Reviews Cancer, 2012
- Interfering with pH regulation in tumours as a therapeutic strategyNature Reviews Drug Discovery, 2011
- Structure of the First Parallel DNA Quadruplex-Drug ComplexJournal of the American Chemical Society, 2003